Pancras C. Wong

12.8k total citations · 4 hit papers
156 papers, 10.2k citations indexed

About

Pancras C. Wong is a scholar working on Cardiology and Cardiovascular Medicine, Hematology and Molecular Biology. According to data from OpenAlex, Pancras C. Wong has authored 156 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Cardiology and Cardiovascular Medicine, 55 papers in Hematology and 52 papers in Molecular Biology. Recurrent topics in Pancras C. Wong's work include Blood Coagulation and Thrombosis Mechanisms (55 papers), Renin-Angiotensin System Studies (38 papers) and Receptor Mechanisms and Signaling (37 papers). Pancras C. Wong is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (55 papers), Renin-Angiotensin System Studies (38 papers) and Receptor Mechanisms and Signaling (37 papers). Pancras C. Wong collaborates with scholars based in United States, Germany and Sweden. Pancras C. Wong's co-authors include Andrew T. Chiu, Ruth R. Wexler, David J. Carini, Pieter B.M.W.M. Timmermans, William F. Herblin, John V. Duncia, A.L. Johnson, Roger Smith, William A. Price and P.B.M.W.M. Timmermans and has published in prestigious journals such as Circulation, Blood and Stroke.

In The Last Decade

Pancras C. Wong

156 papers receiving 9.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Angiotensin II receptors and angiotensin II receptor antagonists.

1993 1.6k citations Pancras C. Wong, Andrew T. Chiu et al. profile →
Identification of angiotensin II receptor subtypes

1989 705 citations Andrew T. Chiu, William F. Herblin et al. profile →
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

2008 490 citations Nirmala Raghavan, Donald Pinto et al. profile →
Nonpeptide angiotensin II receptor antagonists

1991 465 citations Pieter B.M.W.M. Timmermans, Pancras C. Wong et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pancras C. Wong United States	46	6.6k	4.0k	2.3k	1.2k	1.1k	156	10.2k
Ruth R. Wexler United States	43	4.5k 0.7×	3.5k 0.9×	1.7k 0.7×	2.0k 1.6×	1.1k 1.1×	180	8.9k
Pierre Savi France	40	2.9k 0.4×	1.3k 0.3×	461 0.2×	452 0.4×	1.2k 1.1×	90	6.1k
Ryszard J. Gryglewski Poland	41	3.1k 0.5×	2.4k 0.6×	1.1k 0.5×	917 0.8×	420 0.4×	141	13.3k
Wolfgang Wienen Germany	28	2.3k 0.3×	1.1k 0.3×	424 0.2×	408 0.3×	440 0.4×	48	4.2k
Philip Wenzel Germany	52	2.2k 0.3×	2.6k 0.7×	1.1k 0.5×	391 0.3×	275 0.3×	196	8.4k
Albert Ferro United Kingdom	39	1.7k 0.3×	1.3k 0.3×	506 0.2×	158 0.1×	325 0.3×	139	4.8k
Sanjay Bhanot United States	50	1.1k 0.2×	5.2k 1.3×	2.7k 1.2×	97 0.1×	408 0.4×	109	11.1k
Stefano Bellosta Italy	34	822 0.1×	2.4k 0.6×	706 0.3×	337 0.3×	152 0.1×	94	7.3k
W. Griffith Humphreys United States	44	716 0.1×	1.6k 0.4×	456 0.2×	335 0.3×	247 0.2×	129	5.7k
Pieter B.M.W.M. Timmermans United States	47	3.9k 0.6×	4.3k 1.1×	1.7k 0.7×	847 0.7×	117 0.1×	180	8.0k

Countries citing papers authored by Pancras C. Wong

Since Specialization

Citations

This map shows the geographic impact of Pancras C. Wong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pancras C. Wong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pancras C. Wong more than expected).

Fields of papers citing papers by Pancras C. Wong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pancras C. Wong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pancras C. Wong. The network helps show where Pancras C. Wong may publish in the future.

Co-authorship network of co-authors of Pancras C. Wong

This figure shows the co-authorship network connecting the top 25 collaborators of Pancras C. Wong. A scholar is included among the top collaborators of Pancras C. Wong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pancras C. Wong. Pancras C. Wong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wong, Pancras C. & Mimi L. Quan. (2021). Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys. Research and Practice in Thrombosis and Haemostasis. 5(4). e12524–e12524. 6 indexed citations

Allocco, John, et al.. (2020). Experimental model of congestive heart failure induced by transverse aortic constriction in BALB/c mice. Journal of Pharmacological and Toxicological Methods. 106. 106935–106935. 15 indexed citations

Wong, Pancras C., Carol A. Watson, Jacques Banville, et al.. (2017). Abstract 13794: An Orally-Active Small-Molecule Antagonist of the Platelet Protease-Activated Receptor-4, BMS-986141, Prevents Aeterial Thrombosis With Low Bleeding Liability in Cynomolgus Monkeys. Circulation. 136. 2 indexed citations

Wong, Pancras C., Carol A. Watson, & Earl J. Crain. (2015). The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys. Journal of Thrombosis and Thrombolysis. 41(3). 514–521. 24 indexed citations

Wong, Pancras C., Mimi L. Quan, Carol A. Watson, et al.. (2013). Abstract 9916: Potent Antithrombotic Effect of a Small-molecule, Reversible and Direct Inhibitor of Factor XIa With Minimum Bleeding Time Effect In Rabbit Models of Arterial Thrombosis and Hemostasis. Circulation. 128(suppl_22). 1 indexed citations

Priestley, E. Scott, Jinglan Zhou, Jiacheng Zhou, et al.. (2013). Discovery and gram-scale synthesis of BMS-593214, a potent, selective FVIIa inhibitor. Bioorganic & Medicinal Chemistry Letters. 23(8). 2432–2435. 23 indexed citations

Glunz, Peter W., Xiaojun Zhang, Yan Zou, et al.. (2013). Nonbenzamidine acylsulfonamide tissue factor–factor VIIa inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(18). 5244–5248. 13 indexed citations

Zhang, Donglu, Kan He, Nirmala Raghavan, et al.. (2009). Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. Journal of Thrombosis and Thrombolysis. 29(1). 70–80. 17 indexed citations

Wong, Pancras C., Carol A. Watson, & Earl J. Crain. (2008). Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. Journal of Thrombosis and Haemostasis. 6(10). 1736–1741. 39 indexed citations

10.

Wong, Pancras C., William A. Schumacher, Carol A. Watson, et al.. (2006). Abstract 631: Nonpeptide Factor XIa (FXIa) Inhibitor. In vitro Kinetic Evaluation and in vivo Studies of BMS-262084 on Arterial Thrombosis and Hemostasis in Rabbits. Circulation. 114. 3 indexed citations

11.

Qiao, Jennifer X., Xuhong Cheng, Joanne M. Smallheer, et al.. (2006). Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues. Bioorganic & Medicinal Chemistry Letters. 17(5). 1432–1437. 18 indexed citations

12.

Quan, Mimi L., Patrick Y. S. Lam, Qi Han, et al.. (2004). Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor. Journal of Medicinal Chemistry. 48(6). 1729–1744. 147 indexed citations

13.

Wong, Pancras C., et al.. (1996). ANTITHROMBOTIC ACTIONS OF SELECTIVE INHIBITORS OF BLOOD COAGULATION FACTOR Xa IN RAT MODELS OF THROMBOSIS. Thrombosis Research. 83(2). 117–126. 37 indexed citations

14.

Timmermans, Pieter B.M.W.M., Pancras C. Wong, Andrew T. Chiu, & Ronald D. Smith. (1995). The preclinical basis of the therapeutic evaluation of losartan. Journal of Hypertension. 13(Supplement 1). S1–S13. 21 indexed citations

15.

Santella, Joseph B., John V. Duncia, Carol L. Ensinger, et al.. (1994). Balanced angiotensin II receptor antagonists. III. The effects of substitution at the imidazole 5-position.. Bioorganic & Medicinal Chemistry Letters. 4(18). 2235–2240. 14 indexed citations

16.

Timmermans, Pieter B.M.W.M., Pancras C. Wong, Andrew T. Chiu, William F. Herblin, & Roger Smith. (1993). New perspectives in angiotensin system control.. PubMed. 7 Suppl 2. S19–31. 21 indexed citations

17.

Smith, Roger, Andrew T. Chiu, Pancras C. Wong, William F. Herblin, & Pieter B.M.W.M. Timmermans. (1992). Pharmacology of Nonpeptide Angiotensin II Receptor Antagonists. The Annual Review of Pharmacology and Toxicology. 32(1). 135–165. 224 indexed citations

18.

Cogan, Martin G., Ming-Hong Xie, Fuying Liu, Pancras C. Wong, & Pieter B.M.W.M. Timmermans. (1991). Effects of DuP 753 on Proximal Nephron and Renal Transport. American Journal of Hypertension. 4(4_Pt_2). 315S–320S. 20 indexed citations

19.

Chiu, Andrew T., Dale E. McCall, William A. Price, et al.. (1991). In Vitro Pharmacology of DuP 753. American Journal of Hypertension. 4(4_Pt_2). 282S–287S. 44 indexed citations

20.

Timmermans, Pieter B.M.W.M., David J. Carini, Andrew T. Chiu, et al.. (1990). Nonpeptide Angiotensin II Receptor Antagonists. American Journal of Hypertension. 3(8_Pt_1). 599–604. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact